StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald boosted their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA opened at $4.90 on Wednesday. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $6.75. The company’s fifty day moving average is $4.96 and its 200-day moving average is $5.22. The company has a market capitalization of $285.62 million, a PE ratio of -25.79 and a beta of 0.77.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The firm had revenue of $50.47 million during the quarter. On average, analysts forecast that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Sei Investments Co. raised its holdings in shares of Vanda Pharmaceuticals by 39.6% in the first quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 147,066 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at about $1,158,000. Acadian Asset Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 4.7% in the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock valued at $9,740,000 after buying an additional 107,203 shares during the last quarter. Monaco Asset Management SAM bought a new stake in Vanda Pharmaceuticals during the 2nd quarter worth about $1,090,000. Finally, Empowered Funds LLC raised its holdings in Vanda Pharmaceuticals by 8.2% during the 1st quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock worth $827,000 after purchasing an additional 15,215 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.